Table 1.
Calcimycin-induced apoptosis in various cell lines or pretreatments
| Percentage of apoptosis
|
|||
|---|---|---|---|
| Row number | Different cell lines or pretreatment conditions | 0.01% DMSO 18 hr | 5 μM calcimycin 18 hr |
| 1 | N/N1003A | 3 ± 0.5 | 50 ± 3 |
| 2 | N/N1003A + UO126 | 3.6 ± 1 | 12 ± 4 |
| 3 | N/N1003A + PD 169316 | 3.5 ± 0.8 | 48 ± 4.8 |
| 4 | N/N1003A + SP600125 | 3 ± 1.2 | 49 ± 4.2 |
| 5 | pCMV-N/N1003A | 3 ± 1.6 | 50 ± 3.5 |
| 6 | pCMV-DNMRAS-N/N1003A | 3 ± 1.5 | 12.8 ± 3 |
| 7 | pCMV-DNMRAF-N/N1003A | 3 ± 1.8 | 11.2 ± 3.5 |
| 8 | pCMV-DNMERK-N/N1003A | 3 ± 1.9 | 10.8 ± 4 |
| 9 | pCMV-p53-N/N1003A | 4 ± 1.8 | 68 ± 4.4 |
| 10 | pCMV-antisense-p53-N/N1003A | 3 ± 1.6 | 24 ± 3.8 |
| 11 | pCI-Bax-N/N1003A | 4 ± 1.9 | 76 ± 6.2 |
| 12 | pCI-antisense-Bax-N/N1003A | 3 ± 1.4 | 22 ± 2.8 |
| 13 | pEGFP-N/N1003A | 3 ± 0.6 | 49.8 ± 4.1 |
| 14 | pEGFB-maB-N/N1003A | 3 ± 0.4 | 14.4 ± 2.4 |
| 15 | pEGFB-maB-N/N1003A + pCMV-Neo | 3 ± 0.6 | 15.2 ± 2.2 |
| 16 | pEGFB-maB-N/N1003A + pCMV-p53 | 4 ± 1 | 29.8 ± 4.2 |